Berlex Foundation Seeks Workshop Applicants
DUMONT, NJ--The Berlex On-cology Foundation is seeking applicants for two workshops: Epidemiology and Clinical Trial Design, to be held August 23-29, 1996, in Brewster, Mass, and The Clinical Pharmacology of Anticancer Drugs, which will take place October 4-8, 1996, in Leesburg, Va.
DUMONT, NJ--The Berlex On-cology Foundation is seeking applicantsfor two workshops: Epidemiology and Clinical Trial Design, tobe held August 23-29, 1996, in Brewster, Mass, and The ClinicalPharmacology of Anticancer Drugs, which will take place October4-8, 1996, in Leesburg, Va.
Aimed at young investigators interested in cancer research, theinteractive workshops offer ample opportunity for one-on-one interfacingwith the faculty, as well as peer-to-peer networking.
The awards cover travel expenses, lodging, meals, course syllabus,and textbooks. The application deadlines are May 30, 1996, forthe epidemiology workshop, and June 30, 1996, for the anticancerdrugs course. Twenty scholars will be selected for each program.
All applicants must be currently enrolled in an accredited oncologytraining program and should possess a demonstrated interest incancer research. Applicants must supply a current curriculum vitae,letter of recommendation from the department chairman, and a one-pageletter describing the applicant's purpose in attending the program.
For more information, contact Svetlana Lisanti, Berlex OncologyFoundation, 80 W. Madison Ave., Dumont, NJ 07628, or telephone201-385-0006.
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
